This review concluded that transient elastography had excellent diagnostic accuracy for cirrhosis. This was independent of underlying liver disease, but accuracy for diagnosis of significant fibrosis depended on underlying disease. Because the review considered overall accuracy and not relative numbers of false positives and false negatives, and the analysis was not fully described, these conclusions should be interpreted cautiously.
Study selection
Studies that evaluated transient elastography and used liver biopsy as a reference standard were eligible for inclusion. Included studies were required to use comparable liver biopsy staging systems (METAVIR, Ishak, Brunt, Ludwig's, Knodell, Desmet or Scheuer) , to assess diagnostic accuracy for fibrosis stage (F≥2, F≥3, F=4) according to METAVIR or a comparable staging system and/or assess diagnostic accuracy for a fibrosis stage based on a defined cut-off point for liver stiffness. Diagnostic accuracy data could be reported as sensitivity and specificity or area under the receiver operating characteristic curve (AUROC).
Where reported, mean age of study participants ranged from 11 to 60 years and the proportion of male participants ranged from 8% to 83%. Most of the included studies (36/50) used the METAVIR staging system for liver biopsies. Histopathological diagnoses varied and included: HIV; alcoholic steatohepatitis; non alcoholic steatohepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; non alcoholic fatty liver disease; hepatitis C virus (HCV); hepatitis B virus (HBV); haemochromatosis; and cystic fibrosis.
The authors did not state how many reviewers assessed studies for inclusion.
Assessment of study quality
Methodological quality of included studies was assessed using the QUADAS tool for assessment of aspects reporting quality, appropriateness of participant spectrum, use of an appropriate reference standard, blinding of test interpreters, avoidance of verification biases, avoidance of disease progression bias and accounting for withdrawals and uninterpretable test results; results were published online (supplementary table 1).
The authors did not state how many reviewers performed quality assessment.
Data extraction
Data were extracted on sensitivity and specificity and AUROC of transient elastography for different fibrosis stages (F≥2, F≥3, F=4), based on the METAVIR staging system. Data extraction was undertaken by one reviewer and checked by a second; disagreements were resolved by discussion. 
Methods of synthesis
Studies that used histology scoring systems with a range from 0 to 4 (METAVIR, Desmet and Scheuer, Knodell, Brunt, Ludwig's) were used to generate a pooled estimate of AUROC and 95% confidence intervals (CIs), using a DerSimonian and Laird random effects model weighted by sample size. Ishak score (scale 0 to 6), was transferred into METAVIR with Ishak F≥3 equivalent to METAVIR F≥2, Ishak F≥4 equivalent to METAVIR F≥3 and Ishak F≥5 equivalent to METAVIR F=4.
Potential causes of between-study heterogeneity were explored: underlying liver disease (studies of patients with hepatitis C virus only, studies with mixed populations that included hepatitis C virus, studies that excluded hepatitis C virus); staging system used; country; publication status; mean body mass index of participants; mean age of participants; fibrosis stage; gender distribution; mean or median length of liver biopsy specimen; proportion of liver biopsy failures; proportion of FibroScan (transient elastography) failures; and QUADAS criteria.
A summary receiver operating characteristic (SROC) curve was calculated from all studies in which sensitivity and specificity were known for at least one cut-off level, using the Littenberg and Moses model weighted by sample size.
Results of the review
Fifty studies (15 full publications and 35 abstracts, participant numbers ranged from 30 to 1,345) were included in the review. Selection criteria, details of the reference standard and blinding of interpreters of the index test and reference standard were poorly reported by most included studies.
Diagnosis of significant fibrosis (F≥2): Pooled AUROC was 0.84 (95% CI 0.82 to 0.86; 35 studies). Underlying liver disease, histological staging system used and the country in which studies were conducted were significant contributors to between-study heterogeneity; other factors were not significant contributors to heterogeneity.
Diagnosis of severe fibrosis (F≥3): Pooled AUROC was 0.89 (95% CI 0.88 to 0.91; 35 studies). The histological staging system used was a significant contributor to between-study heterogeneity and mean participant body mass index was of borderline significance; other factors were not significant contributors to heterogeneity.
Diagnosis of cirrhosis (F=4):
Pooled AUROC was 0.94 (95% CI 0.93 to 0.95; 38 studies). The country in which studies were conducted was a significant contributor to between-study heterogeneity and the histological staging system used was of borderline significance; other factors were not significant contributors to heterogeneity.
Analysis of the impact of study quality found that differences in the QUADAS criteria on selection criteria, appropriate reference standard, partial verification bias, reference execution details, test review bias, diagnostic review bias and a number of uninterpretable results were significant contributors to between-study heterogeneity. The sum of all QUADAS items had no significant influence on the AUROC.
